| Value | ₹300.0 Cr |
|---|---|
| new pet pharmacy stores planned | 8.0 stores |
BSE filing, NSE: FREDUN. Summary written from the filing by ALFA Finder's alert engine.
Fredun Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,471.70
- Market cap
- ₹2,109 Cr
- Revenue (annual)
- ₹635.5 Cr
- Net profit (annual)
- ₹32.62 Cr
- P/E (TTM)
- 48.1×Sector 46.1×
- Promoter holding
- 43.62%-0.95% QoQ
- FII holding
- 0.69%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fredun Pharmaceuticals Ltd
All →Fredun Pharmaceuticals Convertible Warrants
Fredun Pharmaceuticals allotted 44,000 equity shares to three non-promoter investors on conversion of 14,667 warrants. The conversion follows the 1:2 bonus issue, which adjusted warrant entitlements.
Fredun Pharmaceuticals Other Announcement
Fredun Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ending September 30, 2026. The disclosure provides the equity holding structure for shareholders.
Fredun Pharmaceuticals Other Announcement
Fredun Pharmaceuticals filed a compliance certificate under Regulation 74(5) of the SEBI (DP) Regulations, 2018. It confirms the processing of dematerialized shares for the quarter.
Fredun Pharmaceuticals Business Update
Fredun Pharma announces strategic pet-care acquisitions, capacity expansion, and a 100% branded portfolio target by 2029. H1 FY27 business update outlines multi-pillar growth transformation.
- manufacturing infrastructure (Palghar plant)
- 90000 sq. ft.
Fredun Pharmaceuticals Capital Structure Change
Fredun Pharmaceuticals allotted 1,82,400 equity shares upon the conversion of 60,800 warrants. The company received total consideration of ₹7.60 Crore for this warrant conversion.
- Value
- ₹7.60 Cr
Fredun Pharmaceuticals Capital Structure Change
Fredun Pharmaceuticals has allotted 1,82,400 equity shares following the conversion of 60,800 warrants into equity shares, completing the preferential issue conversion process.
Other acquisition announcements
All →Hexaware Technologies Acquisition
Hexaware Technologies announced amalgamation of two wholly owned step-down subsidiaries into its Canadian subsidiary. No cash consideration is involved, and the merger is internal group restructuring.
Zensar Technologies Acquisition
Zensar's board approved merging its wholly owned subsidiary M3bi India into the parent. No consideration or share issuance is involved, and NCLT sanction is pending.
ICICI Lombard General Insurance Company Acquisition Worth ₹172 Cr
ICICI Lombard disclosed that it acquired Rs.172 Crore of State Bank of India shares on October 28, 2026, in its ordinary-course investment function. Its cumulative holding in SBI is now 0.02%.
- Value
- ₹172.0 Cr
- Execution
- Investment made in multiple tranches over a period of time
Emkay Global Financial Services Acquisition Worth ₹30 Cr
Emkay Global will buy Emkay Capital Private Limited for Rs 30 Crore in cash. The related-party deal is expected to complete within 90 days.
- Value
- ₹30.00 Cr
Jindal Stainless Acquisition Worth ₹5.08 Cr
Jindal Stainless acquired an additional ~7% stake in Ampin C&I Three, taking its holding to 24.21%. The cash cost is ~₹5.08 crore for a 40 MW captive solar project.
- Value
- ₹5.08 Cr
- solar captive capacity
- 40.0 MW
OnEMI Technology Solutions Acquisition Worth ₹624.1 Cr
OnEMI Technology's board approved a Rs.624.15 Crore cash investment in Si Creva Capital Services, subscribing 23,37,516 equity shares at Rs.2,670.14 each. Completion is indicated by end-December 2026.
- Value
- ₹624.1 Cr
- Execution
- By end of December 2026